Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 14 (7), 797-806

Adenosine A2A Agonists in Development for the Treatment of Inflammation

Affiliations
Review

Adenosine A2A Agonists in Development for the Treatment of Inflammation

Courtney M Lappas et al. Expert Opin Investig Drugs.

Abstract

Extracellular adenosine binds specifically to a family of four G protein-coupled cell-surface adenosine receptors (ARs). As the activation of the A2AAR modulates the activity of multiple inflammatory cells including neutrophils, macrophages and T lymphocytes, the receptor is considered to be a promising pharmacological target for the treatment of inflammatory disorders. Although adenosine binds nonselectively to all four AR subtypes, A2AAR selective agonists have been developed and shown to inhibit multiple manifestations of inflammatory cell activation including superoxide anion generation, cytokine production and adhesion molecule expression. A2AAR agonists are also vasodilators, but the inhibition of inflammation occurs at low doses that produce few or no cardiovascular side effects. Therefore, the selective activation of the A2AAR by these compounds holds significant potential in the treatment of inflammation.

Similar articles

See all similar articles

Cited by 35 articles

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

Feedback